Forecyte Bio, a provider of cell and gene therapy contract development and manufacturing, opened its 17,000 sq.-ft., state-of-the-art cGMP facility.    The new production facility consists of individual cleanroom suites for plasmid DNA, viral vectors and cell therapies, as well as lab space for process development and quality control testing. They are equipped with state-of-the-art bioreactors and purification apparatus such as XDR-200 and AKTA Ready to support programs for cell and gene thera...